Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3760/cma.j.issn.1001-0939.2020.03.016 http://scihub22266oqcxt.onion/10.3760/cma.j.issn.1001-0939.2020.03.016 32164092!ä!32164092 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538       Zhonghua+Jie+He+He+Hu+Xi+Za+Zhi 2020 ; 43 (3): 219-222 Nephropedia Template TP {{tp|p=32164092|t=2020. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia |pdf=|usr=}}{{32164092}} gab.com Text Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia JO: Zhonghua Jie He He Hu Xi Za Zhi http://www.kidney.de/pget.php?&tw=1&pmid=32164092 #FOAvip The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality. Twit Text FOAVip Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia ????Zhonghua Jie He He Hu Xi Za Zhi http://www.kidney.de/pget.php?&tw=1&pmid=32164092 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32164092 #FOAvip English Wikipedia <ref>{{Cite pmid|32164092}}</ref> Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia #MMPMID32164092 Sun ML; Yang JM; Sun YP; Su GH Zhonghua Jie He He Hu Xi Za Zhi 2020[Mar]; 43 (3): 219-222 PMID32164092show ga The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality. |*Betacoronavirus/drug effects/pathogenicity[MESH] |*Inflammation/drug therapy/etiology[MESH] |*Peptidyl-Dipeptidase A/drug effects/physiology[MESH] |*Renin-Angiotensin System/drug effects/physiology[MESH] |Angiotensin II[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/*therapeutic use[MESH] |Animals[MESH] |Blood Pressure/drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Lung[MESH] |Peptide Fragments[MESH] |Pneumonia, Viral/*drug therapy/etiology[MESH] |Prognosis[MESH] Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing